The biologic and clinical relevance of cytogenetic analysis in myelodysplastic syndromes (MDS) is well established and karyotype has been identified by the International Prognostic Scoring System (IPSS) as one of the three variables for the definition of prognosis in MDS. The German–Austrian MDS Study Group presented cytogenetic findings in 2,072 patients with MDS, which serve as a basis for the characterization of the cytogenetic subgroups. The availability of new therapeutic options for low- and high-risk MDS targeted against distinct entities characterized by specific chromosome abnormalities, like 5q-deletions, monosomy 7, and complex abnormalities underlines the important role of cytogenetics for the clinical management of MDS. In fact, it is not possible to properly manage MDS withotu obtaining cytogenetics.
Occhipinti E, Correa H, Yu L, Craver R. Comparison of two new classifications for pediatric myelodysplastic and myeloproliferative disorders. Pediatr Blood Cancer. Mar 2005;44(3):240-4.
Galili N, Cerny J, Raza A.Current treatment options: impact of cytogenetics on the course of myelodysplasia.Curr Treat Options Oncol. 2007 Apr;8(2):117-28.